Search Clinical Trials
Withdrawn
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (External Link)
A maximum of 42 subjects will participate in the treatment part of this study. The investigators will collect up to 180 mL of the participants blood. The investigators will use …
Baylor Role:
Lead Sponsor
Withdrawn
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA (External Link)
To prepare the neuroblastoma specific Natural Killer T cells (also called GINAKIT cells), about 80 mL (up to 6 tablespoons) of blood will be collected from the patient. For children, …
Baylor Role:
Lead Sponsor
Withdrawn
Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (External Link)
After the eligible criterion for treatment has been met and a suitable UCB stem donor has been found, the patient will have a central line placed. Research Therapy: After placement …
Baylor Role:
Lead Sponsor